Harrow's Q2 results were solid, but meeting ambitious full-year revenue guidance will require flawless execution amid recent topline misses and a challenging market. VEVYE, IHEEZO, and TRIESENCE are ...
Harrow is a company focused on eye health with a strong distribution platform and CEO ownership. Q3 earnings were below expectations, and guidance was lowered, raising concerns about operational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback